AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 42 min read$TEVA

Shields Matthew sold $532K of TEVA

Shields Matthew (EVP, Global Operations) sold 16,195 shares of TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) at $32.87 ($0.53M total) on 2026-06-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Shields Matthew
Published Jun 4, 2026, 8:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 4, 2026, 8:01 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$TEVA
Neutral
medium confidence
Mentioned
$TEVA
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEVANeutralLow
01

Why it matters

Because the transaction is explicitly under a 10b5-1 plan, it is less likely to reflect new, material information. The main tradable element is potential short-lived sentiment/positioning impact from insider-selling headlines.

02

Market read

Insider selling by a senior executive can move sentiment marginally, but 10b5-1 structure typically limits informational value.

03

What to watch

10b5-1 plans are pre-scheduled and often used for routine diversification/tax planning; the sale size and post-transaction holdings may not indicate a change in fundamentals.

Relevance 6/10Novelty 3/10Timing: After-hours/filing date (June 4) following the June 3 sale.

Background

The article is a SEC Form 4 insider transaction disclosure for TEVA, filed June 4, detailing an executive’s open-market sale executed June 3 under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$TEVANeutralMedium confidence
Context

TEVA insider Matthew Shields (EVP, Global Operations) sold $532K of TEVA shares under a pre-arranged 10b5-1 plan on June 3.

Expected impact

Likely limited immediate price impact; any reaction should be muted unless accompanied by other company-specific news.

Evidence & confidence

The filing is an open-market sale by an executive, explicitly tied to a pre-arranged 10b5-1 plan, which reduces the likelihood of new, time-sensitive information.

Market effects

Sector

Minimal—this is company-specific insider activity without disclosed operational or regulatory developments.

Regional

Minimal—no stated cross-border transaction or regional catalyst.

Global

Minimal—no new global guidance, trial, or deal information is provided.

Counterpoint

What could challenge this read

Some traders may interpret repeated insider selling as a gradual confidence signal, especially if paired with other insider transactions around the same period.

Key entities

  • issuer
    TEVA

    TEVA Pharmaceutical Industries Ltd; the insider sale disclosed on SEC Form 4.

  • insider
    Matthew Shields

    EVP, Global Operations; sold 16,195 shares on June 3 under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TEVA insider trading history →

Related articles

SEP 4
$TEVAMed

S&P upgrades Teva rating on deleveraging and pipeline strength

S&P Global Ratings upgraded Teva Pharmaceutical Industries Ltd. to 'BBB-' from 'BB+', citing strong branded products, generics stabilization, and debt reduction. Teva's key brands generated $3.1B in 2025, with expected growth. The company reduced debt from $29B in 2018 to $17B in 2025 and aims for mid-3x leverage by year-end. S&P forecasts strong cash flow and debt reduction.

investing.com2 min
SEP 4
$TEVAMed

Teva (TEVA) Backed a Bid of Up to $125M in Cash Plus Assumed Liabilities for BioXcel’s Assets. Is Bankruptcy-Sale Risk Worth the At-Home Opportunity?

Teva Pharmaceuticals (TEVA) agreed to a stalking-horse bid of up to $125M for BioXcel Therapeutics' (BTAI) assets, including $57.5M in cash and up to $67.5M in contingent payments. The deal, subject to court approval, includes IGALMI and other assets. The FDA has a 2026 target date for a supplemental application to expand IGALMI's label to at-home use. Competing bids may arise.

finance.yahoo.com3 min
SEP 4
$TEVAMed

S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline

S&P Global Ratings upgraded Teva Pharmaceutical's long-term issuer credit rating to BBB- from BB+, reflecting strong financial performance and debt reduction. This is the third upgrade in recent months, with Teva now holding investment-grade ratings from all major agencies. The company's CFO attributed the upgrades to successful execution of its growth strategy and improved financial profile.

globenewswire.com1 min
SEP 2
$TEVAMedAI 8/10

Teva Stock Drops As Celiac Trial Fails To Impress - TipRanks.com

Teva Pharmaceutical's (TEVA) stock declined despite early-stage positive results from a Phase 2a trial of TEV-408 for celiac disease. Investors were unimpressed due to the lack of later-stage data or a commercialization timeline. The company is focusing on specialty medicines and biosimilars to stabilize growth but faces challenges from debt and generic revenue pressure.

tipranks.com2 min
SEP 2
$TEVAMedAI 8/10

Teva Drug Rises to the Gluten Challenge, Stopping Intestinal Damage in Celiac Disease Trial

Teva Pharmaceutical Industries' experimental drug TEV-53408 met its main goal in a mid-stage trial, preventing intestinal damage in celiac disease patients. The Phase 2a study showed significant improvement in intestinal health and symptom scores compared to placebo. Teva plans further studies and projects peak sales of $1.5B-$2B for the drug, which targets the IL-15 pathway. The company has a deal with Royalty Pharma for up to $500M in support.

medcitynews.com2 min